-
21.发明公开
公开(公告)号：EP3502103A1
公开(公告)日：2019-06-26
申请号：EP17848166.9
申请日：2017-09-08
发明人： DING, Charles Z. , CHEN, Shuhui , HU, Lihong , XU, Zhaobing , LIU, Yingchun , REN, Bingjie , LI, Weidong , LI, Zongbin , ZHAO, Rui , ZHANG, Xiquan
IPC分类号： C07D401/14 , A61K31/506 , A61P35/00
摘要： A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.
-
公开(公告)号：EP3248968A1
公开(公告)日：2017-11-29
申请号：EP16739808.0
申请日：2016-01-22
发明人： CHEN, Shuhui , DING, Charles Z. , YAN, Xiaobing , HUANG, Wei , HU, Guoping , LI, Jian , ZHANG, Xiquan , YANG, Ling , XU, Hongjiang
IPC分类号： C07D413/04 , C07D487/08 , C07D495/04 , C07D513/04 , C07D471/04 , C07D417/04 , C07D413/14 , A61K31/4725 , A61K31/422 , A61K31/4365 , A61K31/437
CPC分类号： C07D413/04 , A61K31/422 , A61K31/4365 , A61K31/437 , A61K31/4725 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D487/08 , C07D495/04 , C07D513/04 , Y02P20/55
摘要： The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.
摘要翻译： 本发明涉及作为HSP90抑制剂的间苯二酚衍生物或其药学上可接受的盐的式（I）所示的化合物。 本发明中的化合物具有抑制热休克蛋白HSP90的活性。 因此，本发明中的化合物用于治疗增殖性疾病如癌症和神经退行性疾病。 本发明进一步提供了用于包含所述化合物的药物组合物的化合物和制备方法，治疗疾病的方法以及包含所述化合物的药物组合物。
-
公开(公告)号：EP4442690A1
公开(公告)日：2024-10-09
申请号：EP22900534.3
申请日：2022-11-30
发明人： LIU, Fei , PENG, Yan , XU, Hongjiang , FENG, Taotao , ZHANG, Xiquan , REN, Cheng , SHI, Wei
IPC分类号： C07D498/22 , C07D519/00 , A61K31/496 , A61K31/4545 , A61K31/5377 , A61P35/00
CPC分类号： A61K31/4545 , A61K31/496 , A61K31/5377 , A61P35/00 , C07D498/22 , C07D519/00
摘要： The present disclosure relates to a compound containing cycloalkyl or haloalkyl, and specifically discloses a compound represented by formula I", a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof in treating tumors.
-
公开(公告)号：EP4410836A1
公开(公告)日：2024-08-07
申请号：EP22875057.6
申请日：2022-09-29
申请人： Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group , CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
发明人： YANG, Anqi , ZHANG, Xiquan , YU, Ding , LV, Peng , WANG, Xunqiang , TIAN, Xin , CHEN, Qin
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： A61K39/395 , C07K16/28 , A61P35/00
摘要： An anti-CD47 antibody for combined treatment of a blood tumor. Provided are the use of the anti-CD47 antibody and a second therapeutic agent in the preparation of a drug for treating a blood tumor in a subject. Provided is a method for treating a blood tumor in a subject, comprising administering a therapeutically effective amount of the anti-CD47 antibody and the second therapeutic agent to a subject. Also provided are a pharmaceutical combination comprising the anti-CD47 antibody and the second therapeutic agent, and a kit.
-
公开(公告)号：EP4410777A1
公开(公告)日：2024-08-07
申请号：EP22872243.5
申请日：2022-09-27
发明人： FENG, Fan , YU, Ding , ZHANG, Xiquan , WANG, Yueting
IPC分类号： C07D231/56 , C07D401/14 , C07D403/14 , A61K31/416 , A61K31/44 , A61K31/445 , A61K31/506 , A61P35/00
CPC分类号： A61K31/416 , A61K31/445 , A61K31/44 , A61K31/506 , A61P35/00 , C07D231/56 , C07D401/14 , C07D403/14
摘要： The present disclosure relates to a combined pharmaceutical composition of a CDK4/6 inhibitor and an aromatase inhibitor, and the use thereof in the treatment of breast cancer. Compared with separate administration of any agent in the composition, the combined pharmaceutical composition of the present disclosure yields a better therapeutic effect on slowing tumor growth or even eliminating tumors.
-
公开(公告)号：EP4201960A1
公开(公告)日：2023-06-28
申请号：EP21857623.9
申请日：2021-08-16
发明人： ZHEN, Zipeng , XIE, Meijuan , DU, Xiuzhen , MA, Yimin , ZHANG, Bing , XU, Tongjie , ZHANG, Xiquan
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61P37/02
摘要： Provided is an immunoglobulin single variable domain and antigen binding molecule binding BCMA, specifically comprising an immunoglobulin single variable domain and antigen binding molecule, a nucleic acid for encoding the binding molecule, a vector containing the nucleic acid, a cell containing the vector, and a pharmaceutical composition containing the above. Further provided is a therapeutic use thereof.
-
公开(公告)号：EP4151654A1
公开(公告)日：2023-03-22
申请号：EP21803875.0
申请日：2021-05-11
发明人： ZHANG, Zhengping , YING, Shusong , XU, Hongjiang , YANG, Ling , ZHANG, Xiquan , GUO, Jun , SHI, Wei , SONG, Wei , ZHOU, Yunyan
IPC分类号： C07K16/28
摘要： Provided is an ST2 antigen binding protein, such as a mouse, human, chimeric or humanized antibody or antigen binding fragment thereof that specifically binds to ST2. Also provided are nucleic acid molecules encoding the above-mentioned antibodies and antigen binding fragments thereof, and an expression vector and host cell for expressing the antibodies or antigen binding fragments thereof. Further provided are methods for preparing and using the antibodies and antigen binding fragments thereof. The methods comprise treating and preventing IL33/ST2-mediated related diseases or conditions.
-
28.发明公开
公开(公告)号：EP3978494A1
公开(公告)日：2022-04-06
申请号：EP20813454.4
申请日：2020-05-22
发明人： LIU, Fei , LIU, Yanlong , XU, Hongjiang , ZHANG, Xiquan , WANG, Shanchun , ZHANG, Jianqing , FENG, Weiwei , WANG, Bin , WANG, Jinan , WANG, Yubing , TANG, Xujing , NIE, Quandeng
IPC分类号： C07D471/04 , C07D211/96 , C07D215/20 , A61K31/404 , A61P35/00
摘要： Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.
-
29.发明公开6-ARYL AMINO PYRIDONE FORMAMIDE COMPOUND CRYSTAL AND PREPARATION METHOD THEREFOR 审中-公开6-芳基氨基吡啶酮甲酰胺化合物晶体及其制备方法
公开(公告)号：EP3178821A1
公开(公告)日：2017-06-14
申请号：EP15830563.1
申请日：2015-08-05
发明人： WANG, Lulu , ZHANG, Xiquan , LIU, Fei , ZHU, Yizhong , GAO, Chao , TANG, Song , ZHU, Bo , TANG, Jianqiu
IPC分类号： C07D491/048 , A61K31/4355 , A61P35/00 , A61P29/00
CPC分类号： C07D491/048 , A61K31/4355 , C07B2200/13
摘要： Provided are 6-aryl amino pyridone formamide compound crystal and a preparation method therefor. In the present invention, 6-(2-chlorine-4-iodopheny amino)-N-(2-hydroxyl ethyoxyl)-5-methyl-4-oxo-4,5-dihydrofuran[3,2-c]pyridine-7-formamide is dissolved in a polar aprotic solvent, a second solvent is added for recrystallization, and a crystal is obtained. The crystallization method is simple to operate and conducive for industrial production. The produced crystal has high purity, good stability, and is conductive for pharmaceutical production and storage.
摘要翻译： 本发明提供6-芳基氨基吡啶酮甲酰胺化合物结晶及其制备方法。 在本发明中，6-（2-氯-4-氨基iodopheny）-N-（2-羟基ethyoxyl）-5-甲基-4-氧代-4,5-二氢呋喃并[3,2-c]吡啶-7- - 甲酰胺溶于极性非质子溶剂中，加入第二溶剂进行重结晶，得到晶体。 结晶方法操作简单，有利于工业生产。 所生产的晶体纯度高，稳定性好，对药物生产和储存具有导电性。
-
公开(公告)号：EP2540717B1
公开(公告)日：2015-05-20
申请号：EP10846385.2
申请日：2010-12-23
发明人： LIU, Yanlong , LIU, Fei , ZHANG, Xiquan
IPC分类号： C07D411/04 , A61P31/12
CPC分类号： C07D411/04
-
-
-
-
-
-
-
-
-
搜索结果
66 条记录 (耗时 0.025 秒)
